<DOC>
	<DOCNO>NCT00497367</DOCNO>
	<brief_summary>The purpose study determine safety feasibility use human TAXUS Petal Paclitaxel-Eluting Bifurcation Coronary Stent System treatment de novo lesion native coronary artery involve major side branch . The TAXUS® Petal™ investigational device indication improve coronary artery luminal diameter maintain side branch access subject symptomatic ischemic disease due discrete atherosclerotic bifurcation lesion</brief_summary>
	<brief_title>Safety Study Assess Feasibility Use Humans TAXUS Petal Bifurcation Coronary Stent System</brief_title>
	<detailed_description>To assess safety feasibility use human TAXUS Petal Paclitaxel-Eluting Bifurcation Coronary Stent System ( TAXUS® Petal™ ) treatment de novo atherosclerotic bifurcation lesion ( visual estimate ) : - Phase 1 : - Main branch : 3.0 3.5 mm RVD lesion length ≤20 mm - Side branch : 2.5 3.5 mm RVD lesion length ≤14 mm - Phase 2 : - Main branch : 3.0 3.5 mm RVD lesion length ≤28 mm - Side branch : 2.25 3.5 mm RVD lesion length ≤14 mm Bifurcation main branch ( MB ) lesion length measure proximal shoulder proximal lesion distal shoulder distal lesion . Bifurcation side branch ( SB ) lesion length measure proximal shoulder side branch ( ostium disease-free ) side branch ostium ( disease continue main branch ) distal side branch shoulder distal lesion . At follow-up , entire stented region use determine MLD % DS .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion Criteria Phases 1 2 Age ≥18 year old ≤80 year old Eligible PCI Acceptable candidate CABG Documented stable angina pectoris ( CCS Classification 1 , 2 , 3 , 4 ) unstable angina pectoris document ischemia ( Braunwald Class IBC , IIBC , IIIBC ) , document silent ischemia LVEF know ≥40 % Clinical angiographic success nontarget lesion ( nontarget lesion treat ) Subject ( legal guardian ) understand study requirement procedure provide write Informed Consent study test procedure perform Subject willing comply followup evaluation Exclusion Criteria Phases 1 2 Contraindication ASA , Thienopyridine derivative ( e.g . Clopidogrel , Ticlopidine ) High risk bleed Known hypersensitivity paclitaxel Known allergy stainless steel Known allergy platinum Previous treatment target vessel antirestenotic drugcoated drugeluting coronary stent Previous treatment target vessel BMS within 9 month index procedure Previous treatment nontarget vessel antirestenotic drugcoated DES within 9 month index procedure Previous treatment intravascular brachytherapy target vessel Planned PCI CABG postindex procedure Planned target vessel treatment unapproved device , directional rotational coronary atherectomy , laser , cut balloon , transluminal extraction catheter Documented MI within 72 hour prior index procedure CK &gt; 2 x ULN + positive CKMB OR CK &gt; 2 x ULN + positive troponin OR If CKMB troponin drawn , patient exclude CK &gt; 2xULN As per protocol definition find Appendix A : CVA within past 6 month Cardiogenic shock Acute chronic renal dysfunction Prior anaphylactic reaction contrast agent Leukopenia Thrombocytopenia Thrombocytosis Active peptic ulcer active GI bleeding Current treatment , pasttreatment within 12 month index procedure , paclitaxel chemotherapeutic agent Anticipated treatment paclitaxel oral rapamycin within 9 month index procedure Subject 's ( men woman ) know intention procreate within 9 month index procedure Positive pregnancy test nursing infant within 7 day prior index procedure Life expectancy le 24 month due medical condition Comorbid condition ( ) could limit subject 's ability comply study followup impact study scientific integrity Currently participate another investigational drug device clinical study Planned surgery time enrollment within next 9 month index procedure Angiographic Inclusion Criteria Phases 1 &amp; 2 Target Lesion ( main / side branch ) : locate native coronary artery must de novo main branch % DS ≥50 % &lt; 100 % bifurcation lesion angle ≥30º ≤90º enrol successful predilatation target vessel Angiographic Inclusion Criteria Phase 1 Main branch target lesion locate parent branch LAD LCx RCA Target lesion locate proximal midsection vessel ( crux RCA [ distal RCA ] allow ) Main branch RVD ≥3.00 mm ≤3.5 mm ; lesion length ≤20 mm ( cover TAXUS® Petal™ stent maximum 1 additional TAXUS stent ≤12 mm length ) Side branch RVD ≥2.5 mm ≤3.5 mm ; lesion length ≤14 mm treat maximum 1 TAXUS stent ≤16 mm length Angiographic Inclusion Criteria Phase 2 Main branch target lesion locate parent branch LAD LCx RCA without restriction Main branch RVD ≥3.00 mm ≤3.5 mm ; lesion length ≤28 mm ( cover TAXUS® Petal™ stent maximum 1 additional TAXUS stent ≤20 mm length ) Side branch RVD ≥2.25 mm ≤3.5 mm ; lesion length ≤14 mm treat maximum 1 TAXUS stent ≤16 mm length Angiographic Exclusion Criteria Phases 1 &amp; 2 Target lesion locate leave main ( protect unprotected ) Medina Classification 0.0.1 Target lesion restenotic Target lesion locate SVG mammary artery graft Target lesion access via SVG mammary artery graft Target lesion &lt; 5 mm BMS Target lesion &lt; 5 mm second side branch vessel ≥1.5 mm diameter Untreated lesion ≥50 % DS think impair flow remain target vessel Target lesion and/or vessel proximal target lesion moderately severely calcified Target lesion and/or target vessel proximal target lesion severely tortuous Main branch target lesion locate within distal &gt; 60° bend target vessel Target vessel angiographic presence probable definite thrombus Unprotected LM disease Protected LM disease target lesion LAD LCx ( subject may enrol lesion target lesion RCA ) Angiographic Exclusion Criteria Phase 1 : Target lesion TIMI flow &lt; 3 Phase 2 : Target lesion TIMI flow &lt; 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>safety</keyword>
	<keyword>feasibility</keyword>
	<keyword>bifurcation</keyword>
	<keyword>lesion</keyword>
	<keyword>de novo</keyword>
	<keyword>intervention</keyword>
</DOC>